Literature DB >> 1634608

A T cell-dependent experimental liver injury in mice inducible by concanavalin A.

G Tiegs1, J Hentschel, A Wendel.   

Abstract

Male NMRI or BALB/c mice developed severe liver injury as assessed by transaminase release within 8 h when an intravenous dose greater than 1.5 mg/kg concanavalin A (Con A) was given. Histopathologically, only the liver was affected. Electron micrographs revealed leukocyte sticking to endothelial cells and bleb formation of hepatocytes. The hepatotoxicity of the lectin correlated neither with its agglutination activity nor with its sugar specificity. Administration of 0.5 mg/kg dexamethasone or 50 mg/kg cyclosporine A or 50 mg/kg FK 506 (Fujimycin) resulted in protection of the animals whereas indomethacin pretreatment failed to protect. Con A hepatitis was accompanied by the release of IL-2 into the serum of the animals. Mice with severe combined immunodeficiency syndrome lacking B as well as T lymphocytes were resistant against Con A. Athymic nude mice with immature T lymphocytes were also resistant. Pretreatment of mice with an antibody against T lymphocytes fully protected against Con A as did monoclonal anti-mouse CD4. Monoclonal anti-mouse CD8 failed to protect. Pretreatment of mice with silica particles, i.e., deletion of macrophages, prevented the induction of hepatitis. These findings provide evidence that Con A-induced liver injury depends on the activation of T lymphocytes by macrophages in the presence of Con A. The model might allow the study of the pathophysiology of immunologically mediated hepatic disorders such as autoimmune chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634608      PMCID: PMC443081          DOI: 10.1172/JCI115836

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  FK-506 enters the clinic.

Authors:  A W Thomson
Journal:  Immunol Today       Date:  1990-02

2.  IL-1 beta is secreted by activated murine macrophages as biologically inactive precursor.

Authors:  H U Beuscher; C Günther; M Röllinghoff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

3.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

Review 4.  Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens.

Authors:  J A Ledbetter; L A Herzenberg
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

5.  Leukocyte alterations do not account for hepatitis induced by endotoxin or TNF alpha in galactosamine-sensitized mice.

Authors:  G Tiegs; M Niehörster; A Wendel
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

6.  Selective binding of concanavalin A to target cell major histocompatibility antigens is required to induce nonspecific conjugation and lysis by cytolytic T lymphocytes in lectin-dependent cytotoxicity.

Authors:  Z Keren; G Berke
Journal:  Cell Immunol       Date:  1984-12       Impact factor: 4.868

7.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

8.  Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin.

Authors:  M A Freudenberg; D Keppler; C Galanos
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

9.  An improved colorimetric assay for interleukin 2.

Authors:  H Tada; O Shiho; K Kuroshima; M Koyama; K Tsukamoto
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

10.  Enhanced phospholipase A2 activity in rat plasma, liver, and intestinal mucosa following endotoxin treatment: a possible explanation for the protective effect of indomethacin in endotoxic shock.

Authors:  K M Shakir; J T O'Brian; S L Gartner
Journal:  Metabolism       Date:  1985-02       Impact factor: 8.694

View more
  294 in total

Review 1.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

Review 3.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis.

Authors:  Hai-Xia Wang; Man Liu; Shun-Yan Weng; Jing-Jing Li; Chao Xie; Hong-Lin He; Wen Guan; Yun-Sheng Yuan; Jin Gao
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

4.  Protective effect of andrographolide against concanavalin A-induced liver injury.

Authors:  Guojun Shi; Zhijian Zhang; Rong Zhang; Xiaofang Zhang; Yan Lu; Jian Yang; Di Zhang; Zhiguo Zhang; Xiaoying Li; Guang Ning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

5.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

6.  Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice.

Authors:  Ricky Cheung; Fran Shen; Joseph H Phillips; Mandy J McGeachy; Daniel J Cua; Paul G Heyworth; Robert H Pierce
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

7.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

8.  The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.

Authors:  Claudia Günther; Gui-Wei He; Andreas E Kremer; James M Murphy; Emma J Petrie; Kerstin Amann; Peter Vandenabeele; Andreas Linkermann; Christopher Poremba; Ulrike Schleicher; Christin Dewitz; Stefan Krautwald; Markus F Neurath; Christoph Becker; Stefan Wirtz
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

9.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

10.  Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.

Authors:  Venkatesh L Hegde; Shweta Hegde; Benjamin F Cravatt; Lorne J Hofseth; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Mol Pharmacol       Date:  2008-04-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.